maria luz calibo
Jul 27, 2011

Teva Profit Little Changed as Rise in European Sales Offsets U.S. Decline - Bloomberg

Teva Pharmaceutical Industries Ltd. (TEVA)’s second-quarter profit was little changed as higher European sales after last year’s acquisition of Ratiopharm GmbH offset declining revenue in the U.S. Earnings excluding some costs climbed 0.3 percent to $984 million, or $1.10 a share, from $981 million, or $1.08, a year earlier, the Petach Tikva, Israel-based company said...